sur Biophytis (EPA:ALBPS)
Biophytis Announces Successful Industrial Transfer of BIO101 Production by Seqens
Paris and Cambridge, June 12, 2024 – Biophytis SA, a clinical-stage biotechnology company focused on age-related diseases, has announced the successful industrial-scale transfer of BIO101 (20-hydroxyecdysone) production by Seqens. Seqens has produced the first GMP-compliant batch at its Villeneuve La Garenne plant.
This batch is set to be used in Biophytis' clinical program for treating respiratory deterioration in Duchenne Muscular Dystrophy (DMD) patients. DMD is a rare genetic disorder leading to severe muscle degeneration. BIO101 shows potential in improving respiratory capacity and quality of life for non-ambulatory patients in advanced stages of DMD.
Biophytis CEO, Stanislas Veillet, stated that this step reinforces their capability to offer unique therapeutic solutions and accelerates the launch of clinical programs. Biophytis is seeking partners and funding to initiate a phase 1-2 clinical trial to evaluate BIO101’s pharmacokinetics, safety, and efficacy in DMD patients.
R. P.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Biophytis